drugset / Trial / NCT05188521
Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus
Non-randomizedSequentialOpen-labelTreatment
Summary
This research study is evaluating the safety and efficacy of Baricitinib in treating Cutaneous Lichen Planus (LP).
Timeline
- Start
- 2022-01-11
- Primary completion
- 2023-05-17
- Completion
- 2023-05-17
Publications
- Zhang N, Stockard AL, Leibovit-Reiben Z, Hwang AS, Kechter JA, Brumfiel CM, Patel MH, Bhullar P, Morken C, Boudreaux BW, Nassir S, Yousif M, Ogbaudu E, Xie F, Zunich S, Branch E, Dueck A, Lehman J, Pittelkow MR, Mangold AR. Repurposing the composite assessment of index lesion severity scoring system in cutaneous lichen planus. Arch Dermatol Res. 2025 Feb 14;317(1):413. doi: 10.1007/s00403-025-03996-4.
- Hwang A, Kechter J, Do T, Hughes A, Zhang N, Li X, Wasikowski R, Brumfiel C, Patel M, Boudreaux B, Bhullar P, Nassir S, Yousif M, DiCaudo DJ, Fox J, Gharaee-Kermani M, Xing X, Zunich S, Branch E, Kahlenberg JM, Billi AC, Plazyo O, Tsoi LC, Pittelkow MR, Gudjonsson JE, Mangold AR. Oral Baricitinib in the Treatment of Cutaneous Lichen Planus. medRxiv [Preprint]. 2024 Jan 11:2024.01.09.24300946. doi: 10.1101/2024.01.09.24300946.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | 2 mg | Oral |
| Subject | Baricitinib | Small molecule | 4 mg | Oral |